Claims for Patent: 7,670,773

Summary for Patent: 7,670,773

Title:	MECP2E1 gene
Abstract:	The invention is a novel MECP2E1 splice variant and its corresponding polypeptide. The invention also includes methods of using these nucleic acid sequences and proteins in medical diagnosis and treatment of neuropsychiatric disorders or development disorders.
Inventor(s):	Minassian; Berge A. (Toronto, CA), Vincent; John B. (Toronto, CA)
Assignee:	Centre for Addiction and Mental Health (Toronto, Ontario, CA) The Hospital for Sick Children (Toronto, Ontario, CA)
Application Number:	11/352,153
Patent Claims:	1. A method of detecting Rett syndrome that is associated with a mutation or deletion in the human MECP2 gene comprising detecting the presence of a non-sense or frameshift mutation or a deletion within exon 1, or in the intron-exon boundary immediately adjacent to exon 1, of a nucleic acid sequence encoding the MeCP2E1 protein having the amino acid sequence of SEQ ID NO: 4 in a sample obtained from a human, wherein the sample nucleic acid sequence is compared to a control nucleic acid sequence and wherein the presence of a mutation or deletion in exon 1, or in the intron-exon boundary immediately adjacent to exon 1, of the sample nucleic acid sequence indicates that the human has Rett syndrome, wherein the mutation or deletion detected is selected from the group consisting of: (1) a deletion of 11 consecutive base pairs in nucleotides 38 to 54 of SEQ ID NO: 1, said deletion causing a truncation of the MeCP2E1 protein of SEQ ID NO: 4 after amino acid 36; (2) a deletion consisting of nucleotides 1-69 of exon 1 of SEQ ID NO: 1; (3) an adenine to thymine change at nucleotide position 8 of SEQ ID NO: 1; and (4) a deletion of a T, G or TG between nucleotide positions 69-71 of SEQ ID NO: 1. 2. The method according to claim 1 comprising: a) amplifying the nucleic acid sequence in the sample with primers X1F (5'-CCATCACAGCCAATGACG-3') (SEQ ID No. 19) and X1R (5'-AGGGGGAGGGTAGAGAGGAG-3') (SEQ ID No. 20) in a polymerase chain reaction; b) amplifying the nucleic acid sequence from the control with the same primers; c) sequencing the amplified sequences; and d) comparing the sample sequence to the control sequence. 3. The method according to claim 1 wherein the MECP2 gene comprises the nucleic acid sequence SEQ ID NO: 1. 4. The method according to claim 3 wherein the presence of the mutation or deletion in the MECP2E1 transcript of the MECP2 gene comprising SEQ ID NO.: 1, wherein the MECP2E1 transcript comprises SEQ ID NO:3, is detected by performing multiplex ligation-dependent probe amplification in all four exons of the MECP2 gene sequence of SEQ ID NO.: 1. 5. A method of detecting the presence of a mutation or deletion in a nucleic acid molecule encoding the MeCP2E1 protein comprising: a) analyzing a test sample containing a nucleic acid sequence encoding the MeCP2E1 protein consisting of SEQ ID NO.: 4 for a mutation or deletion within exon 1, or in the intron-exon boundary immediately adjacent to exon 1, of said nucleic acid sequence; and b) comparing the results of the analysis of the test sample with the results of analysis of a control sample, wherein the control sample comprises the nucleic acid encoding the MeCP2E1 protein consisting of SEQ ID NO.: 4 without a mutation or deletion within exon 1, or in the intron-exon boundary immediately adjacent to exon 1. 6. The method according to claim 5 wherein the nucleic acid molecule encoding the MeCP2E1 protein comprises SEQ ID NO: 3. 7. The method according to claim 5 wherein the mutation or deletion being detected in SEQ ID NO: 1 is selected from the group consisting of: (1) a deletion of 11 consecutive base pairs in nucleotides 38 to 54 of SEQ ID NO: 1, said deletion causing a truncation of the MeCP2E1 protein of SEQ ID NO: 4 after amino acid 36; (2) a deletion consisting of nucleotides 1-69 of exon 1 of SEQ ID NO: 1; (3) an adenine to thymine change at nucleotide position 8 of SEQ ID NO: 1; and (4) a deletion of a T, G or TG between nucleotide positions 69-71 of SEQ ID NO: 1. 8. A method of detecting Rett Syndrome that is associated with a mutation or deletion in the human MECP2E1 gene comprising: a) analyzing a nucleic acid sample obtained from a human for the presence or absence of a mutation or deletion in exon 1 or in the intron-exon boundary immediately adjacent to exon 1 of the MECP2E1 transcript of the MECP2 gene comprising SEQ ID NO: 1; and b) comparing the results of step a) with results of analysis of a control nucleic acid sample, wherein the detection of a mutation or deletion selected from the group consisting of: (1) a deletion of 11 consecutive base pairs in nucleotides 38 to 54 of SEQ ID NO: 1, said deletion causing a truncation of the MeCP2E1 protein of SEQ ID NO.: 4 after amino acid 36; (2) a deletion consisting of nucleotides 1-69 of exon 1 of SEQ ID NO: 1; (3) an adenine to thymine change at nucleotide position 8 of SEQ ID NO: 1; and (4) a deletion of a T, or TG between nucleotide positions 69-71 of SEQ ID NO: 1 indicates that the human has Rett syndrome. 9. The method of claim 1 wherein the nucleic acids are extracted from a cell sample prior to analysis. 10. The method of claim 1 wherein the nucleic acids in the samples are amplified prior to analysis. 11. The method of claim 8 wherein the nucleic acids are extracted from a cell sample prior to analysis. 12. The method of claim 8 wherein the nucleic acids in the samples are amplified prior to analysis.

Details for Patent 7,670,773

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2024-02-17
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2024-02-17
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2024-02-17